Roivant Sciences Ltd. (ROIV) saw its stock price plummet by 5.13% in pre-market trading on Monday following the release of its disappointing first-quarter financial results for the fiscal year 2026. The biopharmaceutical company reported a wider-than-expected loss and a significant decline in revenue, causing investor concern.

For the quarter ended June 30, 2025, Roivant reported a net loss of $273.9 million, or $0.33 per share, compared to a net income of $95.3 million, or $0.13 per share, in the same period last year. The loss was larger than the FactSet analyst consensus estimate of a $0.28 loss per share. Revenue for the quarter fell sharply to $2.17 million, down from $8 million a year earlier and well below the $7.3 million analysts had expected.

Despite the disappointing results, Roivant's CEO Matt Gline emphasized the company's ongoing clinical progress and preparations for the potential launch of brepocitinib, a drug anticipated to benefit patients with high unmet needs. The company also reported a strong cash position of $4.5 billion, which it believes will support its operations into profitability. Additionally, Roivant completed a $1.5 billion share repurchase program and announced plans for a new $500 million buyback program. However, these positive aspects were overshadowed by the larger-than-expected quarterly loss, leading to the significant drop in stock price.